Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 228.31%.

  • Voyager Therapeutics' EBIT Margin fell 1723600.0% to 228.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 446.84%, marking a year-over-year decrease of 4523900.0%. This contributed to the annual value of 104.11% for FY2024, which is 1529100.0% down from last year.
  • Voyager Therapeutics' EBIT Margin amounted to 228.31% in Q3 2025, which was down 1723600.0% from 704.33% recorded in Q2 2025.
  • Voyager Therapeutics' EBIT Margin's 5-year high stood at 1584.71% during Q4 2022, with a 5-year trough of 3244.68% in Q1 2022.
  • Its 5-year average for EBIT Margin is 621.28%, with a median of 393.62% in 2021.
  • In the last 5 years, Voyager Therapeutics' EBIT Margin plummeted by -28510600bps in 2022 and then surged by 33263400bps in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBIT Margin stood at 20.31% in 2021, then soared by 7702bps to 1584.71% in 2022, then plummeted by -96bps to 60.03% in 2023, then tumbled by -1116bps to 610.05% in 2024, then surged by 63bps to 228.31% in 2025.
  • Its last three reported values are 228.31% in Q3 2025, 704.33% for Q2 2025, and 533.74% during Q1 2025.